Amparo García-Gallego
Research Subjects
Amparo García-Gallego has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Abraham José Paredes-Fuentes
Division of Inborn Errors of Metabolism-IBC, Department of Biochemistry and Molecular Genetics, CDB, Hospital Clínic de Barcelona, 08036 Barcelona, Spain
1 shared publication - Adoracion Blanco Alvarez
Haematology Molecular Genetics Unit, Department of haematology, Hospital Universitari Vall d’Hebron (HUVH), Experimental Haematology, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain
1 shared publication - Ana Argudo-Ramírez
Section of Inborn Errors of Metabolism-IBC, Department of Biochemical and Molecular Genetics, Hospital Clínic de Barcelona, Centre de Diagnòstic Biomèdic, Barcelona, Spain
1 shared publication - Anabel Rodríguez-Pebé
Pediatric Hematology Department, Consorci Sanitari del Maresme, 08304 Mataró, Spain
1 shared publication - Anna Andrés-Masó
Pediatric Department, Hospital Santa Caterina, Institut d’Assistència Sanitària, 17190 Salt, Spain
1 shared publication - Anna Collado Gimbert
Rare Anemia Research Laboratory, Vall D'hebron Institut de Recerca Barcelona Spain
1 shared publication
Latest Publications
- Open Access
- 3 October 2024
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 10 (4) , 69
Newborn Screening for Sickle Cell Disease in Catalonia between 2015 and 2022—Epidemiology and Impact on Clinical Events
In 2015, Catalonia introduced sickle cell disease (SCD) screening in its newborn screening (NBS) program along with standard-of-care treatments like penicillin, hydroxyurea, and anti-pneumococcal vaccination. Few studies have assessed the clinical impact of introducing NBS programs on SCD patients. We analyzed the incidence of SCD and related hemoglobinopathies in Catalonia and the change in clinical events occurring after introducing NBS. Screening 506,996 newborns from 2015 to 2022, we conducted a retrospective multicenter study including 100 screened (SG) and 95 unscreened (UG) SCD patients and analyzed SCD-related clinical events over the first six years of life. We diagnosed 160 cases of SCD, with an incidence of 1 in 3169 newborns. The SG had a significantly lower median age at diagnosis (0.1 y vs. 1.68 y, p < 0.0001), and initiated penicillin prophylaxis (0.12 y vs. 1.86 y, p < 0.0001) and hydroxyurea treatment earlier (1.42 y vs. 4.5 y, p < 0.0001). The SG experienced fewer median SCD-related clinical events (vaso-occlusive crisis, acute chest syndrome, infections of probable bacterial origin, acute anemia requiring transfusion, acute splenic sequestration, and pathological transcranial Doppler echography) per year of follow-up (0.19 vs. 0.77, p < 0.0001), a reduced number of annual emergency department visits (0.37 vs. 0.76, p < 0.0001), and fewer hospitalizations (0.33 vs. 0.72, p < 0.0001). SCD screening in Catalonia’s NBS program has effectively reduced morbidity and improved affected children’s quality of life.
- 3 October 2024
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 10 (4) , 69
Open AccessNewborn Screening for Sickle Cell Disease in Catalonia between 2015 and 2022—Epidemiology and Impact on Clinical Events
In 2015, Catalonia introduced sickle cell disease (SCD) screening in its newborn screening (NBS) program along with standard-of-care treatments like penicillin, hydroxyurea, and anti-pneumococcal vaccination. Few studies have assessed the clinical impact of introducing NBS programs on SCD patients. We analyzed the incidence of SCD and related hemoglobinopathies in Catalonia and the change in clinical events occurring after introducing NBS. Screening 506,996 newborns from 2015 to 2022, we conducted a retrospective multicenter study including 100 screened (SG) and 95 unscreened (UG) SCD patients and analyzed SCD-related clinical events over the first six years of life. We diagnosed 160 cases of SCD, with an incidence of 1 in 3169 newborns. The SG had a significantly lower median age at diagnosis (0.1 y vs. 1.68 y, p < 0.0001), and initiated penicillin prophylaxis (0.12 y vs. 1.86 y, p < 0.0001) and hydroxyurea treatment earlier (1.42 y vs. 4.5 y, p < 0.0001). The SG experienced fewer median SCD-related clinical events (vaso-occlusive crisis, acute chest syndrome, infections of probable bacterial origin, acute anemia requiring transfusion, acute splenic sequestration, and pathological transcranial Doppler echography) per year of follow-up (0.19 vs. 0.77, p < 0.0001), a reduced number of annual emergency department visits (0.37 vs. 0.76, p < 0.0001), and fewer hospitalizations (0.33 vs. 0.72, p < 0.0001). SCD screening in Catalonia’s NBS program has effectively reduced morbidity and improved affected children’s quality of life.